个人中心 - 老虎社区

carchoo

IP属地：未知

帖子 · 47帖子 · 47
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- carchoocarchoo
  ·2021-11-11
  Flight to somewhere?
  Singapore Airlines' Q2 loss narrows on cost cuts, air travel pick-up
  Nov 11 (Reuters) - Singapore Airlines Ltd (SIA) said on Thursday market conditions were improving af
  Singapore Airlines' Q2 loss narrows on cost cuts, air travel pick-up
  2,034 评论
  2
  分享
  举报
- carchoocarchoo
  ·2021-11-11
  $Naked Brand(NAKD)$Sigh
  2,109 评论
  点赞
  分享
  举报
- carchoocarchoo
  ·2021-11-09
  $Naked Brand(NAKD)$NAKD CAR TO THE MOON
  1,399 评论
  2
  分享
  举报
- carchoocarchoo
  ·2021-11-04
  $BlackBerry(BB)$Come on let’s fly to the moon
  2,399 评论
  1
  分享
  举报
- carchoocarchoo
  ·2021-11-01
  $Ree Automotive Ltd(REE)$Fly?
  3,991 评论
  点赞
  分享
  举报
- carchoocarchoo
  ·2021-10-31
  $Tiger Brokers(TIGR)$When are you going back up?
  2,061 评论
  6
  分享
  举报
- carchoocarchoo
  ·2021-10-22
  $Tiger Brokers(TIGR)$When are we going to the moon?
  1,905 1
  3
  分享
  举报
- carchoocarchoo
  ·2021-10-20
  $Tiger Brokers(TIGR)$TIME TO FLY
  2,044 1
  8
  分享
  举报
- carchoocarchoo
  ·2021-10-18
  $Tiger Brokers(TIGR)$UP UP UP
  1,885 评论
  点赞
  分享
  举报
- carchoocarchoo
  ·2021-10-15
  Ok cool
  1 Beaten-Down Stock With 10X Potential
  This biotech is down, but it isn't out just yet.
  1 Beaten-Down Stock With 10X Potential
  1,751 评论
  2
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3569485137179617","uuid":"3569485137179617","gmtCreate":1606576291134,"gmtModify":1615385613260,"name":"carchoo","pinyin":"carchoo","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":390,"tweetSize":47,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.99%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":"80.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":870445111,"gmtCreate":1636644097089,"gmtModify":1636644118251,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"Flight to somewhere?","listText":"Flight to somewhere?","text":"Flight to somewhere?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870445111","repostId":"1156547758","repostType":4,"repost":{"id":"1156547758","kind":"news","pubTimestamp":1636629604,"share":"https://ttm.financial/m/news/1156547758?lang=&edition=full","pubTime":"2021-11-11 19:20","market":"sg","language":"en","title":"Singapore Airlines' Q2 loss narrows on cost cuts, air travel pick-up","url":"https://stock-news.laohu8.com/highlight/detail?id=1156547758","media":"Reuters","summary":"Nov 11 (Reuters) - Singapore Airlines Ltd (SIA) said on Thursday market conditions were improving af","content":"<p>Nov 11 (Reuters) - Singapore Airlines Ltd (SIA) said on Thursday market conditions were improving after it reported a narrower second-quarter loss due to cost-cutting efforts, record cargo revenue and an improvement in passenger numbers from a low base.</p>\n<p>The net loss of S$427.6 million ($315.6 million) for the three months to Sept. 30 was down from a record S$2.34 billion loss a year earlier, when COVID restrictions hammered air travel and the airline took large impairment charges on older planes.</p>\n<p>It posted a net profit of S$94.5 million in the September quarter of 2019.</p>\n<p>Revenue doubled in the second quarter to S$1.53 billion due to strong cargo demand and a four-fold rise in passenger numbers from a very low base.</p>\n<p>The airline said monthly operating cashflows were near breakeven levels and it expected passenger capacity to reach 43% of pre-pandemic levels by December, serving half of its previous destinations.</p>\n<p>In September, passenger capacity reached around 32% of pre-pandemic levels, though on average it filled only 20% of the seats on its planes.</p>\n<p>Singapore has recently opened vaccinated travel lanes without quarantine with more than a dozen countries including Britain, the United States, Germany, Australia and South Korea.</p>\n<p>Neighbouring Malaysia will be added to the list from Nov. 29, allowing for more flights between Singapore and Kuala Lumpur, one of the world’s busiest international routes before the pandemic.</p>\n<p>The airline will restart Singapore-London flights on its flagship Airbus SE A380 super-jumbos on Nov. 18 and will fly them to Sydney from Dec. 1.</p>\n<p>SIA, like Hong Kong-based rival Cathay Pacific Airways Ltd , has no domestic market and has been hard-hit by border closures.</p>\n<p>Singapore has capped daily arrivals for the vaccinated travel lanes, meaning the allowable traffic is in the single-digit percentages of pre-pandemic passenger numbers.</p>\n<p>But it is an encouraging sign for travel in the Asia-Pacific region, which had had some of the world’s toughest border controls during the pandemic.</p>\n<p>SIA’s management team will hold a results briefing for analysts and media on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Airlines' Q2 loss narrows on cost cuts, air travel pick-up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Airlines' Q2 loss narrows on cost cuts, air travel pick-up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 19:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/singapore-air-results/update-1-singapore-airlines-q2-loss-narrows-on-cost-cuts-air-travel-pick-up-idUSL1N2S20OY><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 11 (Reuters) - Singapore Airlines Ltd (SIA) said on Thursday market conditions were improving after it reported a narrower second-quarter loss due to cost-cutting efforts, record cargo revenue and...</p>\n\n<a href=\"https://www.reuters.com/article/singapore-air-results/update-1-singapore-airlines-q2-loss-narrows-on-cost-cuts-air-travel-pick-up-idUSL1N2S20OY\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"C6L.SI":"新加坡航空公司"},"source_url":"https://www.reuters.com/article/singapore-air-results/update-1-singapore-airlines-q2-loss-narrows-on-cost-cuts-air-travel-pick-up-idUSL1N2S20OY","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156547758","content_text":"Nov 11 (Reuters) - Singapore Airlines Ltd (SIA) said on Thursday market conditions were improving after it reported a narrower second-quarter loss due to cost-cutting efforts, record cargo revenue and an improvement in passenger numbers from a low base.\nThe net loss of S$427.6 million ($315.6 million) for the three months to Sept. 30 was down from a record S$2.34 billion loss a year earlier, when COVID restrictions hammered air travel and the airline took large impairment charges on older planes.\nIt posted a net profit of S$94.5 million in the September quarter of 2019.\nRevenue doubled in the second quarter to S$1.53 billion due to strong cargo demand and a four-fold rise in passenger numbers from a very low base.\nThe airline said monthly operating cashflows were near breakeven levels and it expected passenger capacity to reach 43% of pre-pandemic levels by December, serving half of its previous destinations.\nIn September, passenger capacity reached around 32% of pre-pandemic levels, though on average it filled only 20% of the seats on its planes.\nSingapore has recently opened vaccinated travel lanes without quarantine with more than a dozen countries including Britain, the United States, Germany, Australia and South Korea.\nNeighbouring Malaysia will be added to the list from Nov. 29, allowing for more flights between Singapore and Kuala Lumpur, one of the world’s busiest international routes before the pandemic.\nThe airline will restart Singapore-London flights on its flagship Airbus SE A380 super-jumbos on Nov. 18 and will fly them to Sydney from Dec. 1.\nSIA, like Hong Kong-based rival Cathay Pacific Airways Ltd , has no domestic market and has been hard-hit by border closures.\nSingapore has capped daily arrivals for the vaccinated travel lanes, meaning the allowable traffic is in the single-digit percentages of pre-pandemic passenger numbers.\nBut it is an encouraging sign for travel in the Asia-Pacific region, which had had some of the world’s toughest border controls during the pandemic.\nSIA’s management team will hold a results briefing for analysts and media on Friday.","news_type":1,"symbols_score_info":{"C6L.SI":0.9}},"isVote":1,"tweetType":1,"viewCount":2034,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870903173,"gmtCreate":1636565301468,"gmtModify":1636565301525,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>Sigh","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>Sigh","text":"$Naked Brand(NAKD)$Sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870903173","isVote":1,"tweetType":1,"viewCount":2109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844475629,"gmtCreate":1636456346263,"gmtModify":1636456346435,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>NAKD CAR TO THE MOON","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>NAKD CAR TO THE MOON","text":"$Naked Brand(NAKD)$NAKD CAR TO THE MOON","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844475629","isVote":1,"tweetType":1,"viewCount":1399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848459342,"gmtCreate":1636022301977,"gmtModify":1636022302152,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>Come on let’s fly to the moon","listText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>Come on let’s fly to the moon","text":"$BlackBerry(BB)$Come on let’s fly to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848459342","isVote":1,"tweetType":1,"viewCount":2399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843002935,"gmtCreate":1635780315238,"gmtModify":1635780315238,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/REE\">$Ree Automotive Ltd(REE)$</a>Fly?","listText":"<a href=\"https://laohu8.com/S/REE\">$Ree Automotive Ltd(REE)$</a>Fly?","text":"$Ree Automotive Ltd(REE)$Fly?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843002935","isVote":1,"tweetType":1,"viewCount":3991,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840159531,"gmtCreate":1635609655332,"gmtModify":1635609655332,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>When are you going back up?&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>When are you going back up?&nbsp;","text":"$Tiger Brokers(TIGR)$When are you going back up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840159531","isVote":1,"tweetType":1,"viewCount":2061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853709969,"gmtCreate":1634833092197,"gmtModify":1634833092349,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>When are we going to the moon?","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>When are we going to the moon?","text":"$Tiger Brokers(TIGR)$When are we going to the moon?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/853709969","isVote":1,"tweetType":1,"viewCount":1905,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859110850,"gmtCreate":1634668842603,"gmtModify":1634668842738,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>TIME TO FLY","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>TIME TO FLY","text":"$Tiger Brokers(TIGR)$TIME TO FLY","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859110850","isVote":1,"tweetType":1,"viewCount":2044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850173944,"gmtCreate":1634567556829,"gmtModify":1634567681151,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>UP UP UP&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>UP UP UP&nbsp;","text":"$Tiger Brokers(TIGR)$UP UP UP","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850173944","isVote":1,"tweetType":1,"viewCount":1885,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824341402,"gmtCreate":1634284919851,"gmtModify":1634284919939,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569485137179617","idStr":"3569485137179617"},"themes":[],"htmlText":"Ok cool&nbsp;","listText":"Ok cool&nbsp;","text":"Ok cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824341402","repostId":"2175194207","repostType":4,"repost":{"id":"2175194207","kind":"highlight","pubTimestamp":1634264640,"share":"https://ttm.financial/m/news/2175194207?lang=&edition=full","pubTime":"2021-10-15 10:24","market":"us","language":"en","title":"1 Beaten-Down Stock With 10X Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","media":"Motley Fool","summary":"This biotech is down, but it isn't out just yet.","content":"<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially <a href=\"https://laohu8.com/S/AONE.U\">one</a> with a relatively small stock market capitalization.</p>\n<p>Of course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, <b>Axsome Therapeutics</b> (NASDAQ:AXSM), and consider why this company still has some serious potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e718d88c283ce5cf7cc7b8239f5cdcf4\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>AXSM data by YCharts.</span></p>\n<h2>A series of setbacks</h2>\n<p>Axsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.</p>\n<p>Then the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.</p>\n<p>But because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome.&nbsp;The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.</p>\n<h2>Why Axsome Therapeutics' shares could soar</h2>\n<p>Despite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.</p>\n<p>There are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.</p>\n<p>Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.</p>\n<p>True, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony.&nbsp;The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.</p>\n<p>Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.</p>\n<h2>Bargain hunters need not look elsewhere</h2>\n<p>With Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.</p>\n<p>On the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.</p>\n<p>Given the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175194207","content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","news_type":1,"symbols_score_info":{"AXSM":0.9}},"isVote":1,"tweetType":1,"viewCount":1751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}